Edition:
United States

Humana Inc (HUM)

HUM on New York Consolidated

253.64USD
15 Dec 2017
Change (% chg)

$3.03 (+1.21%)
Prev Close
$250.61
Open
$252.56
Day's High
$257.24
Day's Low
$250.00
Volume
2,329,548
Avg. Vol
1,135,220
52-wk High
$264.56
52-wk Low
$186.25

Chart for

About

Humana Inc. is a health and well-being company. The Company's segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $36,235.04
Shares Outstanding(Mil.): 142.86
Dividend: 0.40
Yield (%): 0.63

Financials

  Industry Sector
P/E (TTM): -- 23.98 16.04
EPS (TTM): -- -- --
ROI: -- -0.07 34.69
ROE: -- 16.16 15.46

BRIEF-Humana Prices $800 Million Debt Offering

* ‍SENIOR NOTES ARE COMPRISED OF $400 MILLION OF COMPANY'S 2.900 PERCENT SENIOR NOTES, DUE 2022, AT 99.830 PERCENT OF PRINCIPAL AMOUNT​

Dec 14 2017

Fitch Rates Humana's Senior Notes Issuance 'BBB'

(The following statement was released by the rating agency) CHICAGO, December 14 (Fitch) Fitch Ratings has assigned a 'BBB' rating to Humana Inc.'s (HUM) issuance of $800 million of senior unsecured notes. The existing ratings assigned to HUM and its subsidiaries are not affected by today's rating action. The Outlook is Stable. Fitch expects proceeds from the issuance to be used primarily to fund the previously announced redemption of the company's $500 million of 7.20% senior notes due June 15,

Dec 14 2017

BRIEF-Humana Inc Files Prospectus Supplement Related To A Potential Two-Part Notes Offering

* HUMANA INC FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART NOTES OFFERING - SEC FILING Source text: (http://bit.ly/2o9hPlN) Further company coverage:

Dec 14 2017

BRIEF-Humana Announces $3 Billion Share Repurchase Authorization

* HUMANA INC - ‍REPURCHASE AUTHORIZATION WITH EXPIRATION DATE OF DECEMBER 31, 2020 Source text for Eikon: Further company coverage:

Dec 14 2017

AT&T/Time Warner antitrust trial set for March

WASHINGTON The trial to determine if the U.S. Department of Justice can stop AT&T Inc's $85 billion purchase of media company Time Warner Inc will begin on March 19 with no decision expected before the companies' April 22 deadline to complete the deal, a federal judge said on Thursday.

Dec 07 2017

UPDATE 3-AT&T/Time Warner antitrust trial set for March

WASHINGTON, Dec 7 The trial to determine if the U.S. Department of Justice can stop AT&T Inc's $85 billion purchase of media company Time Warner Inc will begin on March 19 with no decision expected before the companies' April 22 deadline to complete the deal, a federal judge said on Thursday.

Dec 07 2017

BRIEF-Humana-Expects Net Membership Gains For Individual Medicare Advantage Membership For Year Ended Dec 31,2018 To Reach Higher End Of Projected Growth Range

* HUMANA-EXPECTS NET MEMBERSHIP GAINS FOR INDIVIDUAL MEDICARE ADVANTAGE MEMBERSHIP FOR YEAR ENDED DEC 31,2018 TO REACH HIGHER END OF PROJECTED GROWTH RANGE

Dec 05 2017

CVS-Aetna deal to change how big employers buy health benefits

NEW YORK CVS Health Corp's proposed purchase of Aetna Inc will change the way many major U.S. corporations buy health coverage for employees and raise new questions over the cost of those benefits, benefit consultants said. | Video

Dec 04 2017

BRIEF-Humana Issued Redemption Notices To Redeem Its $300 Mln Aggregate Principal Amount Of 6.30 Pct Senior Notes Due Aug 1, 2018

* HUMANA INC - ‍ ISSUED REDEMPTION NOTICES TO REDEEM ITS $300 MILLION AGGREGATE PRINCIPAL AMOUNT OF 6.30% SENIOR NOTES DUE AUGUST 1, 2018 - SEC FILING

Nov 29 2017

BRIEF-Humana elects Karen Desalvo to board of directors

* Humana Inc - ‍Desalvo's election brings number of Humana directors to 12​ Source text for Eikon: Further company coverage:

Nov 13 2017

Earnings vs. Estimates